Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

Comment by javaman12on Dec 21, 2024 2:48pm
30 Views
Post# 36373738

RE:Asks were at .07 at close Last trades at close CDN

RE:Asks were at .07 at close Last trades at close CDN It's good to see the share price moving again in the right direction! Recently, there has been a huge volume in the buying of BioVaxys shares.

Hopefully, the share price will soon gain some greater traction before some big pharma company decides to buy us all out!

A substantial premium to the current share price will have to be paid for this gem of a company!

With the recent acquisition of these GMP lipids, their conception of a better bioactive molecular delivery platform may soon be tested out! 

https://www.newswire.ca/news-releases/biovaxys-secures-gmp-grade-lipid-supply-for-production-of-dpx-based-vaccines-in-advance-of-preclinical-and-clinical-program-ramp-up-815585781.html

Biovaxys only has to demonstrate that its product works the best to get a licence from any big pharmaceutical company that is looking to maximize its own product develop goals!

Human allergy trials may soon be done. Perhaps even a one time vaccination for the Avian flu may  be introduced to cure a more immediate concern? The US food industry may soon need to have this issue addressed to prevent a possible crisis in their cattle and poultry industry.

Health concerns and their remediation will never go away. And BioVaxys may help to provide the very best of solutions!

                      Biovaxys shareholders, who would choose to be sellers, open your eyes!

                                                               All the best! Java

                                                      
<< Previous
Bullboard Posts
Next >>